News | October 26, 2009

Results Presented On Use Of FlexStent in the Superficial Femoral Artery

October 27, 2009 – Interim six-month clinical results on the use of the FlexStent Femoropopliteal Self Expanding Stent System in the Superficial Femoral Artery were presented today at the VIVA conference by William Gray, M.D., of New York Columbia-Presbyterian Hospital. The clinical results originated from Flexible Stenting Solutions, Inc (“FSS”) first-in-man study conducted in New Zealand by principle investigator Dr. Andrew Holden of Auckland City Hospital, and FSS’s supplementary study conducted in Germany by principle investigator Dierk Scheinert, M.D., of University of Leipzig – Heart Center.

The primary objective at both sites was to evaluate the safety and efficacy of the FlexStent as measured by the absence of in-stent binary restenosis (patency) using duplex ultrasound (DUS) at one-, six- and 12-month intervals. The primary efficacy endpoint is based on DUS peak systolic velocity ratio (PSVR). Several secondary efficacy endpoints were evaluated. The absence of stent fracture was also evaluated at both sites at the six and 12 month visits using standard X-ray evaluation methods.

The pooled clinical results from the Auckland and Leipzig sites were 92.3 percent patency and a 0 percent fracture rate for an average lesion length of 86.8 mm. Both sites reported only one in-stent stenosis with 13 patients at each site for a total of 26 patients at six months to date. Freedom from major adverse cardiac events (MACE) at both sites was 100 percent.

“We are pleased with the favorable clinical results of the FlexStent to date and its positive impact on our patients,” Dr. Holden said.

The FlexStent U.S. clinical trial, led by principle investigator William Gray, M.D., director of endovascular intervention at New York Columbia-Presbyterian Hospital in the Center for Interventional Vascular Therapy, will commence in early 2010.

For more information: www.flexiblestent.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init